65 results about "Tumor cell death" patented technology

Methods of inducing a cancer-specific immune response are disclosed through administration of an immune stimulant in the context of tumor cell death induction. Currently used clinical methods of inducing localized tumor cell death are modified to optimize immune response induction. One embodiment of the invention discloses pharmaceutical compositions and kits for modifying the palliative procedure of transarterial chemoembolization so as to promote uptake and presentation of tumor antigens in an immunostimulatory microenvironment, thereby allowing for induction of T cell, B cell and NK responses, which control not only local, but also systemic tumor growth and metastasis.

This document provides methods and materials related to treating cancer. For example, methods and materials that include using CD40L polypeptide, an hsp70 polypeptide, and a cytotoxic polypeptide to trigger an immune response directed against cancer cells are provided.

The invention provides a genetically engineered cell membrane nano vesicle and preparation and an application thereof. The nano vesicle is composed of biological cell membranes, and the surface is transferred with a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a programmed death receptor 1 (PD-1), and internal entrapment catalase (CAT). TRAIL can specifically induce tumor celldeath, release tumor antigens and "dangerous signal molecules", and triggers an immune response; the PD-1 can combines PD-L1 protein on cancer cells, and blocks related immunosuppressive pathways; andthe CAT can catalyze H2O2 of a tumor site to produce oxygen, improves a tumor hypoxic environment, and enhances infiltration of immune cells. Through organic integration of the functions, effective elimination of tumor cells and rapid activation of an autoimmune system are achieved, and a multi-point synergistic anti-tumor effect is exerted.

A method of determining whether a tumor will be non-responsive to sunitinib therapy including detecting whether IL-8 or MMP12 expression levels in the tumor are elevated as compared to a control, that is, a tumor having elevated IL-8 or MMP12 levels will be non-responsive to sunitinib. Also, a method for inhibiting the proliferation or causing the death of a sunitinib-resistant tumor cell by contacting the cell with an agent that inhibits IL-8 or MMP12 activity and with sunitinib, whereby proliferation of the tumor cell is inhibited or the tumor cell dies. Further, the invention includes compositions and kits that include an IL-8 inhibitor or an MMP12 inhibitor and sunitinib, and related methods of treatment.

Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

This invention provides a method for increasing apoptosis in tumor cells and a method of decreasing a size of a tumor, said methods comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone. This invention also provides a method of treating cancer in a subject which comprises a method according to either of the above-described methods. This invention provides a method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly. This invention provides a pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and at least one ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceutically acceptable carrier.

The subject invention concerns N-thiolated β-lactam compounds of formula A, wherein R1is a hydrocarbon group having 1-8 carbon atoms; R3 is an organothio group; and R4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, and analogs and pharmaceutically acceptable salts, esters and amides thereof. The subject invention also concerns methods for inducing tumor cell death or inhibiting tumor cell proliferation, and methods for inducing DNA damage, inhibiting DNA replication, activating p38 MAP kinase, or activating caspase cascade activation, or releasing cytochrome C from mitochondria into the cytoplasm in a tumor cell. Methods for treating cancer using N-thiolated β-lactam compounds, as well as pharmaceutical compositions comprising the same are further disclosed.

The invention discloses a purpose of a polyether compound in medicine preparation and an anti-tumor medicine screening method. The medicine is used for regulating and controlling at least one of the following signal channels: a calcium ion signal channel, a Wnt signal channel, a Hippo signal channel, a TNF signal channel, a VEGF signal channel, a p53 signal channel, an NF-kappa B signal channel, an Ras signal channel, an mTOR signal channel, an RNA degradation signal channel, a PPAR signal channel, a cAMP signal channel, an HIF-1 signal channel, an Insulin signal channel, an AMPK signal channel, an Rap1 signal channel, an apoptosis signal channel, a cell cycle signal channel, a cGMP-PKG signal channel, a DNA copying signal channel, an MAPK signal channel, a PI3K-Akt signal channel and an autophagy signal channel. The polyether compound provided by the invention can cause the tumor cell death through regulating and controlling various signal channels; and a better anti-cancer effect isachieved.

The invention relates to a secretion type eucaryon expression vector for recombining tumor chalone-tumor necrosis factor and a preparation method and the application thereof, and discloses the secretion type eucaryon expression vector of the tumor chalone (tumstatin) and human tumor necrosis factor (TNF-Alpha) and the method of preparing fused protein. Tumstatin-TNF can respectively interact with an AlphavBeta3 receptor on the surface of a neovascularization endothelial cell and a tumor cell death receptor in a highly specific way. A fractional step cloning method is adopted to construct secretion type tumor chalone and the human tumor necrosis factor to syncretize a gene vector and the expression is performed in a eukaryotic cell. The tumor chalone is combined with the AlphavBeta3 receptor on the surface of tumor tissue neovascularization endothelial cell, so that a tumor tissue vascular endothelial cell and a tumor cell can be specifically killed, and the antitumor effect and the tumor angiopoiesis inhibiting effect can be achieved.

This invention provides methods and reagents for inducing cell death in tumor cells. The invention provides said reagents relating to inducing tumor cell death that are antibodies to a specific target, L1CAM, and methods for using said antibodies for inducing cell death. Pharmaceutical compositions of the L1CAM antibodies for use in the practice of the methods of the invention are also disclosed.

The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.

Extracts from an indigenous Jamaican plant that exhibit an anti-tumor activity and / or an anti-inflammatory activity and, more particularly, an extract of Jamaican Ball Moss (Tillandsia Recurvata) that has a therapeutic pharmacological activity, in particular an anti-cancerous activity by inducing tumorous cell death by apoptosis, and active compounds isolated thereof are described. Furthermore, methods for the extraction of the extracts are disclosed. Also, a pharmaceutical composition or product for the treatment of cancer which includes an effective amount of the described extract or an active compound thereof, a therapeutic compound and optionally a pharmaceutical acceptable carrier are described.

The invention discloses composition based on main components of Pu'er tea and the application thereof. The composition comprises tea brown pigment, tea polysaccharide, tea polyphenol, caffeine, gamma-aminobutyric acid and gallic acid. A wild type mouse embryo fibroblast is utilized to test the killing effect of DNA toxicity chemical substance to normal cells and the effect that the composition provided by the invention protects the normal cells from DNA damage and prevents apoptosis; the result shows that the composition provided by the invention can effectively prevent the normal cell death caused by DNA toxicity chemical substance; and further research shows that the composition provided by the invention does not protect tumor cell death caused by the DNA toxicity chemical compound, conversely, the composition provided by the invention can promote the killing effect of the DNA toxicity chemical compound to the tumor cells. Therefore, the composition can be used for protecting the normal cells during the chemotherapy of tumor patients and alleviating toxic side effects caused by tumor chemotherapy, and meanwhile sensibilizes chemotherapy drug, enhances chemotherapy effect, and improves survival quality of chemotherapy patients.

The invention discloses the application of a phosphorus-based material in preparing medicine for treating tumors. Phosphorus-based materials can be converted to the material producing phosphate ions including in acidic environments, and phosphorus-based materials produce large amounts of phosphate ions through phagocytosis by tumor cells to change the internal and external environment of the cells, thereby inhibiting the proliferation of the tumor cells and inducing the death of the tumor cells. This process has no significant effect on normal cell activity. In the method, the phosphorus-basedmaterial is applied to the preparation of medicine for treating tumors, the amplification and the transfer of the tumor cells can be effectively inhibited, the metastasis of the tumor cells and the relapse of the tumor can be effectively prevented, the tumor effect is improved, and the medicine has small influence on normal cells and tissues during the treatment process, and is safe and reliable.

The subject invention concerns N-thiolated β-lactam compounds of formula A, wherein R1 is a hydrocarbon group having 1–8 carbon atoms; R3 is an organothio group; and R4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, and analogs and pharmaceutically acceptable salts, esters and amides thereof. The subject invention also concerns methods for inducing tumor cell death or inhibiting tumor cell proliferation, and methods for inducing DNA damage, inhibiting DNA replication, activating p38 MAP kinase, or activating caspase cascade activation, or releasing cytochrome C from mitochondria into the cytoplasm in a tumor cell. Methods for treating cancer using N-thiolated β-lactam compounds, as well as pharmaceutical compositions comprising the same are further disclosed.

Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

The invention provides a plasma miRNA biomarker related to colorectal cancer diagnosis and an application thereof, and belongs to the field of biotechnology and oncology. The plasma miRNA biomarker related to colorectal cancer diagnosis is plasma miR-21. The present study suggests that plasma miRNAs are mainly from secretion of tumor tissues or are induced by death and dissociation of tumor cells, but the miRNAs with differential expression in the tissues do not absolutely experience differential expression in the plasma, and some miRNAs are even reverse. Although the miR-21 has been determined to be capable of being used as the marker in colorectal cancer tissues, results in the reports of peripheral plasma samples are not uniform, the innovation of the invention lies in that the expression trend uniformity of the plasma miR-21 and the tissue miR-21 is determined, the plasma miR-21 can be used as a diagnostic marker and is non-invasive, so that the plasma miR-21 can be applied to future clinic.

The invention provides a CaO2@DOX@ZIF-67 nanometer material and a preparation method and application thereof. The nanometer material is prepared through the steps of loading adriamycin on the surfaceof nanometer CaO2 through coordination effects, then adsorbing metal ions through the adriamycin on the surface of the CaO2, and then enabling the metal ions and bridging ligands to be subjected to anin situ reaction. After a nanometer reactor CaO2@DOX@ZIF-67 is transported to a tumor position through a blood circulating system, through EPR effects, the nanometer reactor CaO2@DOX@ZIF-67 is enriched in tumor tissue and taken in by tumor cells, ZIF-67 is slowly decomposed to release out Co<2+> in subacid environment, besides, CaO2@DOX is decomposed to release out DOX, and then CaO2 and water are subjected to a reaction to generate O2 and H2O2, so that the oxygen concentration of the tumor tissue can be increased, tumor hypoxia is overcome, and sensibility of hypoxia tumor cells to chemotherapy medicines is strengthened. The Co<2+> or Fe<3+> can catalyze H2O2 to generate a Fenton like reaction, massive .OH can be generated, tumor cell DNA can be destructed through oxidization, and deathof the tumor cells is promoted.

The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and / or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention include compounds of the formula RY*L (where Y* represents phosphotyrosine), with the R group at the Y-1 position. Peptidomimetics of the invention disrupt Stat3 activation and function. Peptidomimetics of the invention significantly inhibit tumor cell growth and induce tumor cell death.

The present invention relates generally to a method of screening for the level of neoplastic cell death in a subject. More particularly, the present invention provides a method of screening for the level of neoplastic cell death by detecting the level of expression of telomerase protein and / or gene by dead cells in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting telomerase protein and / or nucleic acid molecules.

The invention belongs to the field of biological medicines, and particularly relates to an application of a triterpenoid compound in preparation of antitumor medicines. A structural formula of the triterpenoid compound (tormentic acid) is shown in a formula I; and the tormentic acid is capable of obviously inhibiting proliferation of tumor cells, and significantly promoting apoptosis, so as to cause tumor cell death. The dosage of the tormentic acid is low; the toxic and side effects are lower than those of clinical common chemotherapeutic medicines; and the triterpenoid compound can be used as a novel anti-tumor medicine, is applied to treatment of tumors, and is simple in medication way and easy to operate.

The invention relates to the technical field of medicines, and in particular relates to a pharmaceutical composition, and a preparation method and application thereof. The pharmaceutical composition provided by the invention comprises at least two selected from a group consisting of a substance for triggering tumour cell immunogenic death, an immune checkpoint inhibitor and a substance for degrading extracellular matrix in a tumour area; components are supported by a carrier, and can specifically release drugs in a tumour acidic microenvironment to trigger tumour cell death; and thus, the purpose of treating cancers is achieved. Researches show that combined use of the three components can improve the tumour inhibition effect; and the effect is better than that of the three components which are used independently, or combined use of the two.

Amooranin (AMR) has been found to cause tumor cell death through G2 / M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds, including AMR analogs, can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.

The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.

The embodiment of the invention discloses a mild low-temperature photothermal anti-tumor material GO-FA-SNX2112; a preparation method comprises the steps: uniformly dispersing GO in deionized water byultrasound to prepare a dispersed liquid; adding EDC to the dispersed liquid, and stirring; adding NHS and stirring, then mixing NaOH into the solution and adjusting the pH; mixing FA into the obtained solution; after stirring the obtained solution, removing DMSO by a dialysis method; dissolving SNX2112 in DMSO, dispersing to prepare a solution, and then dispersing GO-FA into deionized water to prepare a dispersed solution; mixing a heat shock protein inhibitor solution and the GO-FA dispersed solution evenly and stirring; and carrying out centrifugation washing of the product by PBS for multiple times, removing the free heat shock protein inhibitor, and finally, preparing GO-FA-SNX2112. The mild low-temperature photothermal anti-tumor material GO-FA-SNX2112 can target to a tumor tissue,plays the functions of activating overautophagy and promoting tumor immunity, and then makes tumor cells die.

The invention demonstrates that canonical Wnt signaling is activated in certain primary tumors and tumor cell lines in the absence of ?-catenin or APC mutations and that inhibition of such activated canonical Wnt signaling in such tumor cells inhibits tumor growth and, at least in some cases, induces death of tumor cells. As further demonstrated herein, the activation of canonical Wnt signaling is associated with a higher rate of cancer recurrence in patients with Stage I Non-Small Cell Lung Cancer (NSCLC), which provides a new method for cancer prognosis, wherein activation of canonical Wnt signaling reflects a more aggressive tumor phenotype suggesting the need for a more aggressive therapy.

The invention discloses a composition for meeting nutritional requirements of cancer patients and a preparation method thereof. The composition comprises the following components in parts by mass: 20-35 parts of ergosterol, 15-25 parts of goose egg albumen powder, 15-20 parts of dehydrated cauliflower granules, 15-18 parts of compound polysaccharide, 12-14 parts of medium-chain fatty acid, 8-10 parts of unsaturated fatty acid, 2-6 parts of complex minerals and 10-16 parts of finely ground whole grain powder. According to the composition, the medium-chain fatty acid and unsaturated fatty acid are taken as main components, endogenous fat balance in the cancer patients can be supplemented by intaking the exogenous fat, the ergosterol can inhibit growth of cancer cells, the raw cauliflower ofthe dehydrated cauliflower granules contains abundant anti-cancer active enzymes, the compound polysaccharide can directly damage tumor cell DNA and induce tumor cell death, and complex probiotics andthe finely ground whole grain powder can effectively promote gastrointestinal motility and improve digestion and absorption capacity.

An agent that stimulates antiviral immunity may be used, for the treatment of cancer. A product comprising an immunostimulant and a vector comprising a transgene that promotes death of neoplastic cells, may also be used for simultaneous, sequential or separate administration in the treatment of cancer.

This invention describes the use of a laser scanning device, for example a laser scanning CYTOMETRY (LSC), with a double-fluorescent labeling technique as a quantitative method that can be used to objectively and accurately measure endothelial cell death, endothelial tumor cell death and blood vessel density of tumor tissue. These parameters can be used as markers of efficacy in tumors treated with anti-angiogenic or traditional therapies and can distinguish patients who respond to these drugs from those who do not.

The invention discloses an application of Brazil green propolis in the preparation of PDT antitumor synergistic drugs. In PDT antitumor treatment, the ratio of used photo sensitizer to Brazil green propolis is 1:27-75. The cell experiment results show that the cooperation of BGP (Brazil green propolis) and PDT can alleviate cell inflammation and promote the death of tumor cells. The animal experiment results show that cooperation of BGP and PDT can inhibit the tumorigenicity of tumor cells.